Contrive Datum Insights has published "Immunoassay Market Size, Share & Industry Analysis, By Product (Reagents & Kits, ELISA Reagents & Kits, Rapid Test Reagents & Kits, ELISPOT Reagents & Kits, Western Blot Reagents & Kits, Other Reagents & Kits, Open Ended Systems, Closed Ended Systems, Software & Services), Specimen (Blood, Urine, Saliva, Other Specimens), Technology (Radioimmunoassay (RIA), Enzyme Immunoassays (EIA)Rapid Test, Chemiluminescence Immunoassays (CLIA), Fluorescence Immunoassays (FIA), Others), Application (Therapeutic Drug Monitoring, Oncology, Cardiology, Endocrinology, Infectious Disease Testing, Autoimmune Diseases, Others), End-use (Hospitals, Blood Banks, Clinical Laboratories, Pharmaceutical and Biotech Companies, Academic Research Centers, Others), and Regional Forecast, 2026-2034". The study sizes the global immunoassay market at USD 33.5 billion in 2025 and projects growth from USD 35.95 billion in 2026 to USD 60.95 billion by 2034, a compound annual growth rate of 6.82% across the forecast period.
Immunoassays are laboratory and point-of-care tests that detect and measure a target antigen or antibody using labeled reagents, typically run on automated analyzers or as single-use cartridges and kits. The category spans reagents, instruments and increasingly software that connects a laboratory's device fleet, taking forms ranging from bench-top chemiluminescence analyzers in hospital laboratories to lateral-flow rapid tests used at the point of care. Buyers include hospital and reference laboratories, blood banks, pharmaceutical and biotech companies running clinical trial assays, and academic research centers.
Rising chronic and infectious disease testing volume
Rising chronic and infectious disease testing volume is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 6.82% a year, the product lines exposed to it move fastest: Software & Services compounds at 9.2%, taking its share of revenue from 9% to 11% and its value from USD 3.02 billion to USD 6.71 billion.
On the upside, the study's bull case assumes companion diagnostic mandates and laboratory automation upgrades roll out faster than the base case, and reagent pricing holds firmer under tighter analyzer-reagent lock-in, which would take 2034 revenue to USD 64.61 billion rather than the USD 60.95 billion base case.
However, tender-based procurement compresses reagent pricing further than the base case assumes, and platform automation upgrades in cost-constrained laboratories are delayed, which would hold 2034 revenue to USD 57.29 billion. ELISA Reagents & Kits, which carries 24% of 2025 revenue, already grows at only 5.23% against the market's 6.82%, so the largest part of the base is also its slowest.
Key Players Compete on ELISA Reagents & Kits Volume and Software & Services Growth
Competition in the global immunoassay market runs along the product axis rather than the regional one. ELISA Reagents & Kits holds 24% of 2025 revenue at USD 8.04 billion and remains the largest line through 2034 at 21%, making it the position hardest for a challenger to take. Software & Services, growing at 9.2%, is where share actually changes hands. A supplier established in one is not thereby established in the other, which is what sustains a field of this size in a market of USD 33.5 billion.
Further Report Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Product | ELISA Reagents & Kits | 24% · USD 8.04 billion | — |
| Specimen | Blood | 68% · USD 22.78 billion | Saliva 10.35% |
| Technology | Chemiluminescence Immunoassays (CLIA) | 42% · USD 14.07 billion | — |
| Application | Infectious Disease Testing | 32% · USD 10.72 billion | Oncology 8.94% |
| End-use | Clinical Laboratories | 36% · USD 12.06 billion | Pharmaceutical and Biotech Companies 8.94% |
- Based on regional analysis, North America led the global immunoassay market in 2025 with 36.1% of global revenue at USD 12.08 billion, reaching USD 20.42 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 25.3% in 2025 to 29.5% in 2034, with revenue growing from USD 8.48 billion to USD 17.98 billion.
- Middle East and Africa remains the smallest region throughout, at 5.9% of 2025 revenue and 5.7% by 2034.
- Software & Services is projected to grow at 9.2% over the forecast period, the fastest of any product line.
- The United States is the largest single country market at USD 10.4 billion in 2025, 31.04% of global revenue.
The report segments the market across five axes; by product, and by specimen, technology, application and end-use; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 57.29 billion and USD 64.61 billion by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.